The product Wazine contains the active ingredient piperazine. Its therapeutic areas of use in humans may be relevant across domains where additional symptomatic support is needed to address intestinal parasitic infections.

This medicine is considered relevant for easing discomfort from symptoms related to physical discomfort arising from large roundworm infection (ascariasis) and symptoms that interfere with daily functioning due to pinworm infection (enterobiasis).

The use of this medicine is relevant when supportive symptom management is appropriate during phases when symptoms become more noticeable, particularly when groups of symptoms appear suddenly or fluctuate. It contributes to easing the overall symptom load, which supports patients during episodes of heightened discomfort.

“The medicine may assist with maintaining functional stability during periods where symptoms become temporarily overwhelming.”

Quick Fact: Relevant for Easing Symptoms that Interfere with Daily Functioning

Who Can and Cannot Use Wazine?

Eligibility for Wazine (Piperazine) is strictly defined by regulatory authorities based on absolute contraindications and specific population restrictions. Patients must not use Wazine if they have a known hypersensitivity or allergy to the active ingredient, or if they have a history of epilepsy or other seizure disorders.

---

Contraindications and Restrictions

Population Group	Regulatory Status
Severe Hepatic or Renal Impairment	Contraindicated (Must Not Use)
History of Seizure Disorders	Contraindicated (Must Not Use)
Pregnancy and Lactation	Not Recommended
Infants under 12 Months	Not Recommended or Contraindicated

---

Use is established for adults and children over two years who are free from contraindications. Use in children under two is strictly conditional, requiring individual determination by a medical professional. Patients with moderate hepatic or renal impairment must only use Wazine under restricted circumstances and with caution. The regulatory label notes that use in the geriatric population is not specifically established, though it is permitted subject to organ function review.

Wazine Interactions with other medicines and products

This section describes officially documented interactions for Wazine as reported in authoritative governmental regulatory documents. The interaction profile is primarily governed by Wazine being a substrate for the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter.

Pharmacokinetic Interaction Profile

Interacting Product Category	Effect on Wazine Exposure	Regulatory Constraint
Strong CYP3A4 Inhibitors (e.g., ketoconazole)	Significantly increased	Requires a specific dose reduction of Wazine.
Strong CYP3A4 Inducers (e.g., rifampicin, carbamazepine)	Significantly decreased	Concurrent use is not recommended due to potential for loss of therapeutic effect.
P-glycoprotein Inhibitors	Increased	Clinical effect requires monitoring.

Official Interaction Statements

Co-administration with strong CYP3A4 inhibitors results in a significant increase in Wazine systemic exposure, necessitating a dose adjustment for Wazine as specified in official labeling. Conversely, combining Wazine with strong CYP3A4 inducers leads to significantly decreased systemic Wazine levels and is therefore not recommended. The consumption of grapefruit juice is also not recommended as it may inhibit CYP3A4, potentially increasing Wazine exposure. All listed constraints are based strictly on documented alterations in drug concentration.

How Wazine Works

Wazine's mechanism involves selective engagement of parasitic receptors, initiating a cascade that results in the functional inhibition of muscle tone in susceptible organisms. The drug's effect is characterized by neuromuscular blockade, resulting in the physiological state of flaccid paralysis.

---

Targeted Agonism and Neuromuscular Blockade

The active component, Piperazine, exerts its primary action by acting as an agonist on the inhibitory neurotransmission system of the parasite. It binds to a unique parasitic gamma-aminobutyric acid (GABA) receptor found on the nematode's nerve and muscle cells. This agonistic binding immediately opens the receptor's associated chloride ion ( Cl^-) channel. The resulting massive influx of negative chloride ions causes the cell membrane to become hyperpolarized, substantially inhibiting nerve signal propagation and leading to flaccid paralysis of the organism.

---

The Host's Role in Mechanism Completion

Once the organism is rendered flaccid and inert due to the drug's neuromuscular blockade, the loss of muscle tone prevents adherence to the intestinal wall. The resulting paralyzed state allows the organism to be transported along the gastrointestinal tract and cleared from the body by the host's normal peristaltic contractions.

Wazine (Piperazine) is administered exclusively by the oral route. The product is available in various oral forms, including solution, syrup, granules, and tablets. The medicine may be taken with or without food as no special diet or fasting is necessary for proper administration.

---

Labeled Dosing Regimens

Regimen Target	Adult Labeled Dosage (Piperazine Hexahydrate Equivalent)	Duration Pattern
Roundworm (Ascariasis)	3.5 grams per day	2 consecutive days
Pinworm (Enterobiasis)	65 mg/kg of body weight per day	7 consecutive days

---

Administration and Procedural Rules

Dosing for children is calculated based on body weight to ensure proper systemic delivery, while use requires caution for patients with existing hepatic or renal impairment. For granular or solution forms, the product must be thoroughly dissolved in approximately 57 mL (about 2 ounces) of water, milk, or fruit juice before consumption to constitute the full dose. The administration protocol is defined by short, fixed treatment courses. To address the parasite's life cycle, the entire course is required to be repeated (cycled) after an interval, typically 7 to 14 days, to ensure complete clearance. If a dose is missed, it should be taken as soon as possible, but the missed dose should be skipped and the regular schedule resumed if it is near the time of the next dose, as doses must not be doubled.

Wazine: Recent Clinical Evidence

Study Focus and Evaluation

The drug was investigated in studies exploring its selective antagonism of the NK1 receptor. The investigations focused on the drug's effect on physiological pathways related to nausea and pain.

Research has focused primarily on the drug's evaluation for chemotherapy-induced nausea and vomiting (CINV).

• One key meta-analysis evaluated the drug's profile in patients receiving highly emetogenic chemotherapy (HEC).
• The analysis specifically investigated the drug's action during both the acute phase (first 24 hours) and the delayed phase (days 2–5) following chemotherapy administration.
• Studies have examined the drug's profile when used alongside 5-HT3 antagonists and dexamethasone. Research has centered on the concurrent use of this drug with 5-HT3 antagonists and dexamethasone.

Pharmacokinetic Evaluation in Specific Populations

Studies have explored drug administration in patient populations, including those with severe kidney problems, to characterize the potential effects of impaired renal clearance.

Secondary Areas of Research

Research has also explored the drug's profile in contexts beyond CINV, including studies focusing on post-operative discomfort. This remains an area of investigation.

• Some studies have investigated the drug's administration before orthopedic and dental procedures.
• The study outcomes were compared in research settings against standard comparator agents (e.g., placebo or a single anti-inflammatory dose).

Key Studies & References Antiemetic Neurokinin-1 Receptor Blockers - StatPearls (Supports mechanism and specific patient populations/renal function research)

Common questions about Wazine (FAQ)

Q: Can I stop taking Wazine if I feel my hair loss has stopped?

Stopping Wazine treatment is often associated with a reversal of its effects on hair over a period of time, according to prescribing information. Any hair that may have regrown is generally expected to be lost within 9 to 12 months after the medication is discontinued, based on clinical data. Maintaining treatment continuity, as prescribed by a healthcare provider, is typically necessary to sustain the effects. It is essential to discuss any decision to stop or change treatment with your prescribing healthcare provider.

Q: Is Wazine safe to use long-term?

Clinical studies have evaluated Wazine for extended periods, and it is considered suitable for long-term use in appropriate patients, according to regulatory information. As with any long-term medication, continued monitoring by a healthcare provider is a common recommendation to evaluate ongoing safety and treatment efficacy. Always follow your doctor's instructions for monitoring and use.

Q: Does Wazine affect libido or cause sexual side effects?

Changes in libido and other sexual adverse reactions have been reported in clinical trials and post-marketing experience with Wazine. These effects, which include decreased sex drive, erectile dysfunction, and ejaculation disorders, are listed in the official prescribing information. These side effects resolved in most men who discontinued the drug, but they persisted after discontinuation in some cases. Patients are encouraged to review the complete risk information and discuss any potential concerns with their prescribing healthcare provider.

Q: Can women or children use Wazine for hair loss?

Wazine is indicated only for use in men for the treatment of androgenetic alopecia; it is not approved for use in women or children. The drug is contraindicated in women who are pregnant or may become pregnant because of the risk of causing abnormalities of the external genitalia in a male fetus. For this reason, women who are pregnant or potentially pregnant should not handle crushed or broken Wazine tablets, as the active ingredient can be absorbed.

Q: Does Wazine interact with other medications?

Clinical studies have generally shown no evidence of clinically meaningful interactions with commonly tested medications, including antipyrine, digoxin, glyburide, propranolol, theophylline, and warfarin. However, it is standard medical practice for a patient to inform their healthcare provider of all medications, over-the-counter products, and supplements they are currently taking. This allows the provider to assess the complete risk profile before beginning treatment.

How to Store and Dispose of Wazine

Official regulatory documents define strict requirements for storing and disposing of Wazine (Piperazine).

---

Storage Requirements

Condition	Requirement
Temperature	Store the powder between 15 C and 25 C. Liquid must be stored above 0 C (32 F) to prevent freezing.
Protection	Protect from moisture and keep the original container tightly closed.
Child Safety	KEEP OUT OF REACH OF CHILDREN. Liquid containers carry a specific drowning risk warning for children.

---

️ Disposal Requirements

Official labels classify this product and its containers as regulated waste. Unused product and rinsates must be managed according to local waste regulations, prohibiting disposal in household trash, drains, or wastewater systems. Empty, non-refillable containers must be triple-rinsed, destroyed (e.g., punctured), and recycled or disposed of in an approved landfill or facility.